Works matching DE "GENENTECH Inc."

Results: 239

Genentech: The Beginnings of Biotech.

Published in:

2014

By:

Yi, Doogab

Publication type:

Book Review

Genentech makes its first-ever acquisition.

Published in:

Nature Biotechnology, 2007, v. 25, n. 1, p. 4, doi. 10.1038/nbt0107-4

By:

Hollmer, Mark

Publication type:

Article

Robbing Peter to pay Paul.

Published in:

Nature Biotechnology, 2006, v. 24, n. 11, p. 1341, doi. 10.1038/nbt1106-1341

By:

Jacobs, Tom

Publication type:

Article

Genentech raises stakes on PARP inhibitors.

Published in:

Nature Biotechnology, 2006, v. 24, n. 10, p. 1179, doi. 10.1038/nbt1006-1179

By:

Sheridan, Cormac

Publication type:

Article

Amgen's TPO mimic faces stiff competition.

Published in:

Nature Biotechnology, 2006, v. 24, n. 9, p. 1044, doi. 10.1038/nbt0906-1044

By:

Lawrence, Stacy

Publication type:

Article

Companies eye slice of age-related macular degeneration market.

Published in:

Nature Biotechnology, 2006, v. 24, n. 9, p. 1041, doi. 10.1038/nbt0906-1041

By:

Waltz, Emily

Publication type:

Article

A historical perspective on convergence technology.

Published in:

Nature Biotechnology, 2006, v. 24, n. 3, p. 280, doi. 10.1038/nbt0306-280

By:

Patton, John S.

Publication type:

Article

GlaxoSmithKline cancer drug threatens Herceptin market.

Published in:

Nature Biotechnology, 2005, v. 23, n. 12, p. 1453, doi. 10.1038/nbt1205-1453

By:

Waltz, Emily

Publication type:

Article

Great company, bad stock.

Published in:

Nature Biotechnology, 2005, v. 23, n. 2, p. 173, doi. 10.1038/nbt0205-173

By:

Jacobs, Tom

Publication type:

Article

People.

Published in:: Nature Biotechnology, 2005, v. 23, n. 2, p. 249, doi. 10.1038/nbt0205-249
Publication type:: Article

The biotech drug market.

Published in:

Nature Biotechnology, 2004, v. 22, n. 12, p. 1496, doi. 10.1038/nbt1204-1496

By:

Lawrence, Stacy

Publication type:

Article

Genentech discloses safety concerns over Avastin.

Published in:

Nature Biotechnology, 2004, v. 22, n. 10, p. 1198, doi. 10.1038/nbt1004-1198

By:

Ratner, Mark

Publication type:

Article

Genentech awarded critical antibody patent.

Published in:

Nature Biotechnology, 2002, v. 20, n. 2, p. 108, doi. 10.1038/nbt0202-108

By:

Robertson, Debra

Publication type:

Article

CD18 trials disappoint again.

Published in:

Nature Biotechnology, 2000, v. 18, n. 8, p. 817, doi. 10.1038/78412

By:

Dove, Alan

Publication type:

Article

Genentech's 2nd IPO.

Published in:

Nature Biotechnology, 1999, v. 17, n. 9, p. 838, doi. 10.1038/12793

By:

Breithaupt, Holger

Publication type:

Article

Genentech relaunched with independence intact.

Published in:

Nature Biotechnology, 1999, v. 17, n. 7, p. 634, doi. 10.1038/10842

By:

Glaser, Vicki

Publication type:

Article

Genentech enlightens other angiogenesis programs.

Published in:

Nature Biotechnology, 1999, v. 17, n. 4, p. 326, doi. 10.1038/7877

By:

Brower, Vicki

Publication type:

Article

Book Review.

Published in:

2012

By:

Crowe, Nathan

Publication type:

Book Review

INNOVATION INC.

Published in:

Berkeley Technology Law Journal, 2017, v. 32, n. 2, p. 713, doi. 10.15779/Z38NP1WJ41

By:

Plamondon Bair, Stephanie

Publication type:

Article

DETHRONING LEAR? INCENTIVES TO INNOVATE AFTER MEDIMMUNE.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 2, p. 971

By:

Dreyfuss, Rochelle Cooper;
Pope, Lawrence S.

Publication type:

Article

CITY OF HOPE V. GENENTECH: KEEPING FIDUCIARY DUTIES WHERE THEY BELONG.

Published in:

Berkeley Technology Law Journal, 2009, v. 24, n. 1, p. 179

By:

McBride, Reed C.

Publication type:

Article

DECLARATORY JUDGMENT ACTIONS IN PATENT CASES: THE FEDERAL CIRCUIT'S RESPONSE TO MEDIMMUNE V. GENENTECH.

Published in:

Berkeley Technology Law Journal, 2008, v. 23, n. 1, p. 161

By:

Saionz, Jennifer R.

Publication type:

Article

Capacity Investment with Demand Learning.

Published in:

Operations Research, 2017, v. 65, n. 1, p. 145, doi. 10.1287/opre.2016.1561

By:

Qi, Anyan;
Ahn, Hyun-Soo;
Sinha, Amitabh

Publication type:

Article

Roche vows to keep Genentech culture.

Published in:

Nature, 2009, v. 458, n. 7236, p. 270, doi. 10.1038/458270a

By:

Hayden, Erika Check

Publication type:

Article

Roche launches hostile bid for Genentech shares.

Published in:: Nature, 2009, v. 457, n. 7230, p. 648, doi. 10.1038/457648a
Publication type:: Article

Making the paper: Wei-Qiang Gao.

Published in:: Nature, 2008, v. 456, n. 7223, p. xiii, doi. 10.1038/7223xiiia
Publication type:: Article

Roche bids for remaining Genentech stake.

Published in:: Nature, 2008, v. 454, n. 7203, p. 381, doi. 10.1038/454381a
Publication type:: Article

Business: Stepping out.

Published in:

Nature, 2008, v. 452, n. 7184, p. 146, doi. 10.1038/452146a

By:

Dalton, Rex

Publication type:

Article

No approval.

Published in:: Nature, 2007, v. 450, n. 7172, p. 935, doi. 10.1038/450935c
Publication type:: Article

Making the paper: Yan Zheng.

Published in:: Nature, 2007, v. 445, n. 7128, p. 11, doi. 10.1038/7128xia
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 443, n. 7113, p. 739, doi. 10.1038/443739a
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 442, n. 7099, p. 123, doi. 10.1038/442123a
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 439, n. 7079, p. 911, doi. 10.1038/439911a
Publication type:: Article

In brief.

Published in:: Nature, 2006, v. 439, n. 7074, p. 265, doi. 10.1038/439265b
Publication type:: Article

Movers.

Published in:

Nature, 2004, v. 428, n. 6982, p. 586, doi. 10.1038/nj6982-586c

By:

Dixit, Vishva

Publication type:

Article

Ranibizumab: A Viewpoint by Steven D. Schwartz.

Published in:: Drugs, 2007, v. 67, n. 8, p. 1207
Publication type:: Article

Genentech.

Published in:

2012

By:

Wieland, Thomas

Publication type:

Book Review

Current Developments in State and Local Tax.

Published in:

Journal of State Taxation, 2015, v. 33, n. 2, p. 7

By:

Bernard, Mary F.;
Nachbar, Mark L.

Publication type:

Article

New indication.

Published in:: 2009
Publication type:: Product Review

FDA actions in brief.

Published in:: Formulary, 2008, v. 43, n. 4, p. 121
Publication type:: Article

Tarceva.

Published in:: Formulary, 2005, v. 40, n. 12, p. 425
Publication type:: Article

A year of novel pharmacologic agents in review.

Published in:: Formulary, 2004, v. 39, n. 12, p. 572
Publication type:: Article

New molecular entities.

Published in:: Formulary, 2004, v. 39, n. 12, p. 568
Publication type:: Article

Sally Smith Hughes, Genentech: The Beginnings of Biotech.

Published in:

2013

By:

Pieters, Toine

Publication type:

Book Review

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Published in:

Drugs in R&D, 2003, v. 4, n. 4, p. 243

By:

Limited, Adis International

Publication type:

Article

Study Aims to Clarify Efficacy, Safety of Eye Drug Treatments.

Published in:

JAMA: Journal of the American Medical Association, 2007, v. 297, n. 14, p. 1538, doi. 10.1001/jama.297.14.1538

By:

Mitka, Mike

Publication type:

Article

Genentech: The Beginnings of Biotech.

Published in:

2012

By:

Mody, Cyrus C. M.

Publication type:

Book Review

Industry Pipeline.

Published in:: Ocular Surgery News, 2010, v. 28, n. 4, p. 34
Publication type:: Article

Specialist gives pearls on as-needed dosing schedule of anti-VEGF.

Published in:

Ocular Surgery News, 2009, v. 27, n. 21, p. 64

By:

Cimberle, Michela

Publication type:

Article

OCT-guided anti-VEGF therapy may result in undertreatment.

Published in:

Ocular Surgery News, 2009, v. 27, n. 21, p. 62

By:

Bechtel, Bryan

Publication type:

Article